scholarly journals LW106, a novel indoleamine 2,3‐dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma‐immune crosstalk and cancer stem cell enrichment in tumour micro‐environment

2018 ◽  
Vol 175 (14) ◽  
pp. 3034-3049 ◽  
Author(s):  
Rong Fu ◽  
Yi‐Wei Zhang ◽  
Hong‐Mei Li ◽  
Wen‐Cong Lv ◽  
Li Zhao ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Tumour Progression ◽  
Indoleamine 2,3 Dioxygenase ◽  
Cell Enrichment

scholarly journals PCGF1 promotes epigenetic activation of stemness markers and colorectal cancer stem cell enrichment

2021 ◽  
Vol 12 (7) ◽  
Author(s):  
Guangyu Ji ◽  
Wenjuan Zhou ◽  
Jingyi Du ◽  
Juan Zhou ◽  
Dong Wu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stem Cell ◽  
Cancer Progression ◽  
Molecular Mechanisms ◽  
Tumour Progression ◽  
Stem Cell Markers ◽  
Epigenetic Regulator ◽  
Cell Enrichment ◽  
Histone Trimethylation

AbstractColorectal cancer (CRC) stem cells are resistant to cancer therapy and are therefore responsible for tumour progression after conventional therapy fails. However, the molecular mechanisms underlying the maintenance of stemness are poorly understood. In this study, we identified PCGF1 as a crucial epigenetic regulator that sustains the stem cell-like phenotype of CRC. PCGF1 expression was increased in CRC and was significantly correlated with cancer progression and poor prognosis in CRC patients. PCGF1 knockdown inhibited CRC stem cell proliferation and CRC stem cell enrichment. Importantly, PCGF1 silencing impaired tumour growth in vivo. Mechanistically, PCGF1 bound to the promoters of CRC stem cell markers and activated their transcription by increasing the H3K4 histone trimethylation (H3K4me3) marks and decreasing the H3K27 histone trimethylation (H3K27me3) marks on their promoters by increasing expression of the H3K4me3 methyltransferase KMT2A and the H3K27me3 demethylase KDM6A. Our findings suggest that PCGF1 is a potential therapeutic target for CRC treatment.

scholarly journals Cancer stem cell enrichment is associated with enhancement of nicotinamide N‐methyltransferase expression

IUBMB Life ◽  
2020 ◽  
Vol 72 (7) ◽  
pp. 1415-1425 ◽  
Author(s):  
Valentina Pozzi ◽  
Eleonora Salvolini ◽  
Guendalina Lucarini ◽  
Alessia Salvucci ◽  
Roberto Campagna ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cell Enrichment

scholarly journals The Culture of Cancer Cell Lines as Tumorspheres Does Not Systematically Result in Cancer Stem Cell Enrichment

PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e89644 ◽  
Author(s):  
Christophe Y. Calvet ◽  
Franck M. André ◽  
Lluis M. Mir
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Cell Enrichment

scholarly journals The Role of Biomaterials on Cancer Stem Cell Enrichment and Behavior

JOM ◽  
2015 ◽  
Vol 67 (11) ◽  
pp. 2543-2549 ◽  
Author(s):  
Faride Ordikhani ◽  
Yonghyun Kim ◽  
Silviya P. Zustiak
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cell Enrichment ◽  
And Behavior

scholarly journals Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer

2014 ◽  
Vol 50 (4) ◽  
pp. 765-773 ◽  
Author(s):  
Michelle M. Rietbergen ◽  
Sanne R. Martens-de Kemp ◽  
Elisabeth Bloemena ◽  
Birgit I. Witte ◽  
Arjen Brink ◽  
...  
Keyword(s):  
Stem Cell ◽  
Human Papillomavirus ◽  
Prognostic Factor ◽  
Cancer Stem Cell ◽  
Oropharyngeal Cancer ◽  
Cell Enrichment

scholarly journals The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer

PLoS ONE ◽  
2020 ◽  
Vol 15 (7) ◽  
pp. e0236187
Author(s):  
Claire A. Walsh ◽  
Nina Akrap ◽  
Elena Garre ◽  
Ylva Magnusson ◽  
Hannah Harrison ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cell Enrichment

scholarly journals Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling

2020 ◽  
Author(s):  
Chaozhi Tang ◽  
Jiakang Ma ◽  
Xiuli Liu ◽  
Zhengchun Liu
Keyword(s):  
Bladder Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Gene Set Enrichment Analysis ◽  
Supervised Machine Learning ◽  
Mesenchymal Transition ◽  
Gene Sets ◽  
Cell Enrichment ◽  
Cell Gene ◽  
Stem Cell Gene

Abstract Background: Bladder cancer (BLCA) is the fifth most common type of cancer worldwide, with high recurrence and progression rates. Although considerable progress has been made in the treatment of BLCA through accurate typing of molecular characteristics, little is known regarding the various genetic and epigenetic changes that have evolved in stem and progenitor cells. To address this issue, we have developed a novel stem cell typing method.Methods: Based on six published genomic datasets, we used 26 stem cell gene sets to classify each dataset. Unsupervised and supervised machine learning methods were used to perform the classification. Results: We classified BLCA into three subtypes—high stem cell enrichment (SCE_H), medium stem cell enrichment (SCE_M), and low stem cell enrichment (SCE_L)—based on multiple cross-platform datasets. The stability and reliability of the classification were verified. Compared with the other subtypes, SCE_H had the highest degree of cancer stem cell concentration, highest level of immune cell infiltration, and highest sensitivity not only to predicted anti-PD-1 immunosuppressive therapy but also to conventional chemotherapeutic agents such as cisplatin, sunitinib, and vinblastine; however, this group had the worst prognosis. Comparison of gene set enrichment analysis results for pathway enrichment of various subtypes reveal that the SCE_H subtype activates the important pathways regulating cancer occurrence, development, and even poor prognosis, including epithelial mesenchymal transition, hypoxia, angiogenesis, KRAS signal upregulation, interleukin 6-mediated JAK-STAT signaling pathway, and inflammatory response. Two identified pairs of transcription factors, GRHL2 and GATA6 and IRF5 and GATA3, possibly have opposite regulatory effects on SCE_H and SCE_L, respectively.Conclusions: The identification of BLCA subtypes based on cancer stem cell gene sets revealed the complex mechanism of carcinogenesis of BLCA and provides a new direction for the diagnosis and treatment of BLCA.

scholarly journals Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation

Oncogene ◽  
2018 ◽  
Vol 38 (1) ◽  
pp. 88-102 ◽  
Author(s):  
Zixing Liu ◽  
Wenling Zhang ◽  
Joshua B. Phillips ◽  
Ritu Arora ◽  
Steven McClellan ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cell Enrichment
Sign in / Sign up

Export Citation Format

Share Document